+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The VPS35 gene and Parkinson's disease

The VPS35 gene and Parkinson's disease

Movement Disorders 28(5): 569-575

Parkinson's disease (PD), the second most common age-related neurodegenerative disease, is characterized by loss of dopaminergic and nondopaminergic neurons, leading to a variety of motor and nonmotor symptoms. In addition to environmental factors, genetic predisposition and specific gene mutations have been shown to play an important role in the pathogenesis of this disorder. Recently, the identification of the vacuolar protein sorting 35 homolog gene (VPS35), linked to autosomal dominant late-onset PD, has provided new clues to the pathogenesis of PD. Here we discuss the VPS35 gene, its protein function, and various pathways involved in Wnt/β-catenin signaling and in the role of DMT1 mediating the uptake of iron and iron translocation from endosomes to the cytoplasm. Further understanding of these mechanisms will undoubtedly provide new insights into the pathogenic mechanisms of PD and may lead to prevention and better treatment of the disorder.

(PDF emailed within 0-6 h: $19.90)

Accession: 036826455

Download citation: RISBibTeXText

PMID: 23536430

DOI: 10.1002/mds.25430

Related references

VPS35 gene variants are not associated with Parkinson's disease in the mainland Chinese population. Parkinsonism & Related Disorders 18(8): 983-985, 2013

A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics 49(11): 721-726, 2013

Increased copper toxicity in Saccharomyces cerevisiae lacking VPS35, a component of the retromer and monogenic Parkinson disease gene in humans. Biochemical and Biophysical Research Communications 476(4): 528-533, 2017

VPS35 mutations in Parkinson disease. American Journal of Human Genetics 89(1): 162-167, 2011

VPS35: A new player in Parkinson's disease. Movement Disorders 26(10): 1803-1803, 2011

VPS35, the Retromer Complex and Parkinson's Disease. Journal of Parkinson's Disease 7(2): 219-233, 2017

Contributions of VPS35 mutations to Parkinson's Disease. Neuroscience 2019, 2019

Screening for VPS35 mutations in Parkinson's disease. Neurobiology of Aging 33(4): 838.E1-5, 2012

Deciphering the role of VPS35 in Parkinson's disease. Journal of Neuroscience Research: -, 2018

Frequency of the D620N mutation in VPS35 in Parkinson disease. Archives of Neurology 69(10): 1360-1364, 2013

Linking the VPS35 and EIF4G1 pathways in Parkinson's disease. Neuron 85(1): 1-3, 2015

Role of the VPS35 D620N mutation in Parkinson's disease. Parkinsonism & Related Disorders 36: 10-18, 2016

VPS35 Parkinson's disease phenotype resembles the sporadic disease. Journal of Neural Transmission 121(7): 755-759, 2015

Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochimica et Biophysica Acta. Molecular Basis of Disease 1863(11): 2791-2795, 2017

The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Movement Disorders 27(6): 800-801, 2012